Tirzepatide (Mounjaro) in BC: Cost, Coverage, and How to Get a Prescription in 2026

Navigating the landscape of new medications, especially those offering significant advancements in managing chronic conditions like Type 2 diabetes and obesity, can be complex for patients in British Columbia. Tirzepatide, known by its brand names Mounjaro and Zepbound, represents a groundbreaking development in this field. As a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, it has shown remarkable efficacy in both glycemic control and weight reduction.

For residents of BC, understanding the specifics of tirzepatide's availability, cost, and insurance coverage is crucial. This comprehensive guide, updated for May 2026, aims to demystify these aspects, providing clear, factual information on how to access this medication in British Columbia. We will delve into its mechanism of action, Health Canada approval status, the current state of BC PharmaCare and MSP coverage, detailed cost breakdowns, comparisons to other popular medications like Ozempic, eligibility criteria, and the pathways to obtaining a prescription, including through traditional healthcare providers and burgeoning telemedicine services.

The introduction of tirzepatide has been met with significant interest due to its impressive clinical trial results, offering new hope for individuals struggling with Type 2 diabetes and the complex challenges of chronic weight management. However, like many innovative therapies, its access and affordability are subject to provincial healthcare policies, private insurance plans, and the evolving pharmaceutical market. This article will equip you with the knowledge needed to have informed discussions with your healthcare provider about whether tirzepatide is the right option for you and how to navigate the process of obtaining it in BC.

What Is Tirzepatide, and How Does It Work?

Tirzepatide is a novel medication that has garnered significant attention for its dual action in managing Type 2 diabetes and promoting substantial weight loss. Understanding its mechanism is key to appreciating its effectiveness.

What Is the Mechanism of Action for Tirzepatide?

Tirzepatide is classified as a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. This dual agonism is what sets it apart from earlier generations of GLP-1 receptor agonists, such as semaglutide (Ozempic/Wegovy), which target only the GLP-1 receptor.

Let's break down what each of these hormones does:

Glucose-dependent Insulinotropic Polypeptide (GIP): GIP is a hormone released by the gut in response to food intake. Its primary role is to stimulate insulin secretion from pancreatic beta cells in a glucose-dependent manner. This means it only prompts insulin release when blood sugar levels are high, reducing the risk of hypoglycemia. GIP also plays a role in energy metabolism, fat deposition, and satiety.
Glucagon-Like Peptide-1 (GLP-1): Similar to GIP, GLP-1 is an incretin hormone released from the gut after eating. It also stimulates glucose-dependent insulin secretion, suppresses glucagon secretion (which prevents the liver from releasing too much sugar), slows gastric emptying (leading to a feeling of fullness), and acts on the brain to reduce appetite and increase satiety.

By activating both the GIP and GLP-1 receptors, tirzepatide leverages the synergistic effects of these two incretin hormones. This combined action leads to:

Enhanced Blood Sugar Control: More robust stimulation of insulin release and suppression of glucagon, leading to better regulation of blood glucose levels in people with Type 2 diabetes.
Significant Weight Reduction: The combined effects on slowing gastric emptying, increasing satiety signals to the brain, and potentially influencing fat metabolism lead to reduced caloric intake and substantial weight loss.
Improved Lipid Profiles: Studies have also shown benefits in improving cholesterol and triglyceride levels.

Tirzepatide is administered once weekly as a subcutaneous injection, typically into the abdomen, thigh, or upper arm. This convenient dosing schedule contributes to better patient adherence.

What Are the Brand Names for Tirzepatide in Canada?

In Canada, tirzepatide is available under two distinct brand names, each approved for specific indications by Health Canada:

Mounjaro: This brand name is approved for the management of Type 2 diabetes mellitus. It is used as an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes. While patients with Type 2 diabetes often experience weight loss on Mounjaro, its primary approved indication is blood sugar management.
Zepbound: This brand name is specifically approved for chronic weight management in adults. It is indicated for adults with obesity (defined as a Body Mass Index, or BMI, of 30 kg/m² or greater) or adults who are overweight (BMI of 27 kg/m² or greater) and have at least one weight-related comorbidity, such as hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease.

It is crucial to understand that Mounjaro and Zepbound contain the exact same active ingredient, tirzepatide, and are available in the same dosage strengths. The distinction in brand names primarily relates to their approved indications and how they are marketed and potentially covered by insurance plans. This dual branding strategy is common in the pharmaceutical industry when a drug demonstrates efficacy for multiple distinct conditions.

Is Tirzepatide Approved in Canada?

Understanding the regulatory status of a medication is paramount for patient safety and access. Health Canada is the federal regulatory body responsible for approving health products, including prescription drugs, for use in Canada.

What Is Health Canada's Approval Status for Mounjaro (Tirzepatide) for Type 2 Diabetes?

Yes, Mounjaro (tirzepatide) has been approved by Health Canada for the management of Type 2 diabetes mellitus. This approval signifies that Health Canada has thoroughly reviewed the clinical trial data submitted by the manufacturer, Eli Lilly, and has determined that the drug is safe, effective, and of high quality for its intended use in improving glycemic control in adults with Type 2 diabetes, when used as an adjunct to diet and exercise.

The approval of Mounjaro for Type 2 diabetes provides an important new treatment option for Canadians living with this chronic condition, especially given its demonstrated efficacy in reducing HbA1c levels and often leading to significant weight loss, which is a common comorbidity for many individuals with Type 2 diabetes.

What Is Health Canada's Approval Status for Zepbound (Tirzepatide) for Obesity/Weight Loss?

Yes, Zepbound (tirzepatide) has also been approved by Health Canada for chronic weight management. This approval specifically targets adults with obesity or those who are overweight with weight-related comorbidities. The detailed criteria for this approval include:

Adults with obesity: Defined as a Body Mass Index (BMI) of 30 kg/m² or greater.
Adults who are overweight: Defined as a BMI of 27 kg/m² or greater, accompanied by at least one weight-related comorbidity. These comorbidities can include conditions such as hypertension (high blood pressure), dyslipidemia (abnormal levels of fats in the blood), obstructive sleep apnea, or established cardiovascular disease.

The approval of Zepbound for weight management is a significant milestone, as it recognizes obesity as a chronic disease requiring medical intervention. This decision was based on robust clinical trial data, particularly from the SURMOUNT program, which demonstrated that tirzepatide led to substantial and sustained weight loss in participants.

It is important for patients and healthcare providers to understand that while Mounjaro and Zepbound contain the same active ingredient, their separate Health Canada approvals are for distinct indications. This distinction can influence prescribing patterns, insurance coverage, and patient eligibility criteria. The approval for both diabetes and obesity underscores tirzepatide's broad therapeutic potential across metabolic health.

Is Tirzepatide Covered by BC PharmaCare or MSP?

Access to prescription medications in British Columbia is often facilitated through BC PharmaCare, the provincial drug plan, or through private insurance plans. Understanding the current coverage status for tirzepatide is crucial for patients considering this medication.

What Is the Current Coverage Status of Mounjaro (Tirzepatide for Diabetes) by BC PharmaCare?

As of March 2026, Mounjaro (tirzepatide for Type 2 diabetes) is under review for coverage under BC PharmaCare's Plan NP.

What does "under review for Plan NP" mean? Plan NP stands for "Non-PharmaCare Benefits." This designation means that while the drug is being evaluated, it is not yet broadly covered under the standard PharmaCare plans (like Fair PharmaCare or Plan W for First Nations Health Authority clients). Coverage under Plan NP often requires a "Special Authority" application by your prescribing physician. This application typically involves demonstrating that the patient meets specific clinical criteria, has tried and failed other covered medications, and that tirzepatide is medically necessary. The review process can take time, and approval for Special Authority is not guaranteed.
Implications for Patients: For patients with Type 2 diabetes, this means that as of May 2026, Mounjaro is not routinely covered by BC PharmaCare without a successful Special Authority application. Patients would likely face significant out-of-pocket costs if they do not qualify for Special Authority or do not have adequate private insurance. This situation can create a barrier to access for many who could benefit from the medication. The BC government, through PharmaCare, aims to ensure that medications are both effective and cost-effective for the healthcare system before granting broad coverage.

Is Zepbound (Tirzepatide for Weight Loss) Covered by BC PharmaCare or MSP?

No, as of May 2026, Zepbound (tirzepatide for obesity/weight loss) is NOT yet covered by BC PharmaCare or MSP. This is a critical point for patients seeking tirzepatide solely for weight management.

Why isn't it covered? Provincial drug plans like BC PharmaCare typically have strict criteria for covering weight loss medications. Historically, weight loss drugs have faced challenges in securing public funding due to perceptions of being "lifestyle" drugs rather than for a chronic medical condition, despite growing recognition of obesity as a complex disease. The high cost of these medications also plays a significant role in coverage decisions for provincial plans.
Implications for Patients: For individuals in BC seeking Zepbound for chronic weight management, the cost will be entirely out-of-pocket unless they have a private insurance plan that specifically includes coverage for weight loss medications. This can represent a substantial financial burden, as the monthly cost of tirzepatide is significant.
BC Government Limitations (2025): It's also important to remember that the BC government proactively limited sales of tirzepatide in 2025. This measure was implemented to preserve the existing supply specifically for diabetes patients, prioritizing their medical need over its use for weight loss, which was a significant concern given global supply chain issues and high demand. While supply may have stabilized, the policy reflects the province's stance on prioritizing medical necessity for publicly funded or controlled medications.

In summary, while tirzepatide is an approved and effective medication, its journey to broad public coverage in BC is ongoing and currently limited, particularly for weight loss indications. Patients are advised to discuss coverage options with their healthcare provider, pharmacist, and private insurance provider to understand their specific situation.

How Much Does Tirzepatide Cost in BC?

The cost of prescription medications can be a significant factor in patient access, especially for those not covered by public or private insurance plans. Tirzepatide, being a new and highly effective drug, comes with a notable price tag.

What Is the Price Breakdown for Tirzepatide Doses in BC?

Eli Lilly, the manufacturer of tirzepatide, implemented a significant price adjustment at the end of 2025 to make the medication more accessible in Canada.

As of December 29, 2025, the Canadian list price for a 4-week supply of Mounjaro/Zepbound starts at $300 CAD for the 2.5mg and 5mg doses. This reduction aimed to standardize and lower the initial cost for patients.

However, the full monthly cost of tirzepatide in BC can range from $300 to $502 CAD per month, depending on the prescribed dose. This pricing structure reflects the general pharmaceutical trend where higher doses, which contain more active drug substance, typically incur a higher cost.

Here's a breakdown of the typical cost range per 4-week supply (one pen containing four weekly doses) in BC, based on dose:

2.5mg/dose (initial dose): Approximately $300 CAD per month
5mg/dose: Approximately $300 CAD per month
7.5mg/dose: Approximately $370 - $400 CAD per month
10mg/dose: Approximately $420 - $450 CAD per month
12.5mg/dose: Approximately $460 - $480 CAD per month
15mg/dose (maximum dose): Approximately $480 - $502 CAD per month

These figures represent the list price and may vary slightly between pharmacies. It's important to remember that these are out-of-pocket costs for patients without any insurance coverage.

Are There Any Savings Programs for Tirzepatide in Canada?

Yes, Eli Lilly has introduced a savings program to help eligible Canadian patients manage the cost of Zepbound.

Zepbound Savings Card: A Zepbound savings card is available for eligible Canadian patients. This program is designed to reduce the out-of-pocket cost for the medication, potentially bringing the price down to as low as $300 per month for eligible individuals. The specifics of eligibility criteria for this savings card would typically involve not having public drug coverage for Zepbound and meeting other program requirements set by Eli Lilly. Patients should inquire with their prescribing physician or pharmacist, or visit the Eli Lilly Canada website for the most up-to-date information on this program.

It is crucial for patients to investigate all available options—including private insurance, provincial drug programs (if eligibility for special authority is met), and manufacturer savings programs—to understand the actual financial impact of tirzepatide. Given that PharmaCare does not currently cover Zepbound for weight loss, and Mounjaro coverage for diabetes is under review, these savings programs can be instrumental in making the medication more accessible for many BC residents.

Tirzepatide vs Ozempic: Which Is More Effective?

The advent of tirzepatide has naturally led to comparisons with existing, highly effective medications in the GLP-1 receptor agonist class, most notably semaglutide (Ozempic/Wegovy). Both drugs have revolutionized the treatment of Type 2 diabetes and obesity, but they differ in their mechanism and, consequently, their efficacy profiles.

What Are the Key Differences in Mechanism Between Tirzepatide and Ozempic?

The primary distinction between tirzepatide and semaglutide lies in their receptor targets:

Tirzepatide (Mounjaro/Zepbound): This is a dual GIP/GLP-1 receptor agonist. As discussed, it activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual action is believed to offer a more comprehensive physiological response, leading to enhanced effects on glucose metabolism and appetite regulation.
Semaglutide (Ozempic/Wegovy): This is a single GLP-1 receptor agonist. It primarily activates the glucagon-like peptide-1 (GLP-1) receptor. While highly effective, it does not engage the GIP pathway.

The hypothesis behind tirzepatide's potentially superior efficacy is that by stimulating both incretin pathways, it can achieve a more pronounced and synergistic effect on insulin secretion, glucagon suppression, gastric emptying, and central appetite control.

How Does Tirzepatide Compare to Ozempic in Terms of Weight Loss and Glycemic Control?

Clinical trials have provided clear head-to-head comparisons, demonstrating that tirzepatide generally exhibits superior efficacy in both glycemic control and weight reduction compared to semaglutide.

1. Weight Reduction:

Tirzepatide: In the SURMOUNT clinical trial program (which focused on weight loss in individuals with obesity or overweight without diabetes), participants on tirzepatide achieved an average body weight reduction of approximately 20-22% from baseline. For example, in the SURMOUNT-1 trial, participants receiving the highest dose (15mg) achieved an average weight loss of 22.5% (24 kg or 52 lbs) over 72 weeks.
Semaglutide (Wegovy): In the STEP clinical trial program (which also focused on weight loss in individuals with obesity or overweight without diabetes), participants on semaglutide (2.4mg weekly, the higher dose approved for weight loss) achieved an average body weight reduction of approximately 15% from baseline. For example, in the STEP 1 trial, participants experienced an average weight loss of 14.9% (15.3 kg or 33.7 lbs) over 68 weeks.

This difference of roughly 5-7 percentage points in average body weight reduction highlights tirzepatide's significant advantage in the realm of weight management.

2. Glycemic Control (for Type 2 Diabetes):

Tirzepatide (Mounjaro): In studies comparing tirzepatide to semaglutide in patients with Type 2 diabetes (e.g., SURPASS-2 trial), tirzepatide consistently showed superior reductions in HbA1c (a measure of average blood sugar over 2-3 months). Patients on tirzepatide often achieved lower HbA1c levels and a higher percentage reached the glycemic target of <7%.
Semaglutide (Ozempic): While Ozempic is highly effective at improving glycemic control and reducing HbA1c, tirzepatide has demonstrated an even greater impact in head-to-head trials.

3. Other Benefits:
Both medications offer cardiovascular benefits, though the long-term head-to-head cardiovascular outcomes are still being studied comprehensively. Both also improve other metabolic markers like blood pressure and lipid profiles.

4. Cost Comparison:
In Canada, the monthly costs for tirzepatide and semaglutide (Ozempic) are roughly similar. While the specific list prices can fluctuate and depend on the dose, patients can expect a comparable financial outlay for either medication if paying out-of-pocket.

Conclusion on Efficacy:
Based on current clinical evidence, tirzepatide appears to be more effective than semaglutide for both weight loss and glycemic control in the populations studied. This enhanced efficacy is attributed to its dual GIP/GLP-1 agonism. However, "more effective" doesn't necessarily mean "better for everyone." The choice between tirzepatide and semaglutide should always be made in consultation with a healthcare provider, considering individual patient characteristics, comorbidities, tolerance to side effects, and specific treatment goals. Both medications represent significant advancements in metabolic health.

Who Qualifies for Tirzepatide in BC?

Obtaining a prescription for tirzepatide in British Columbia, whether for Type 2 diabetes or chronic weight management, depends on meeting specific medical criteria established by Health Canada's approvals and, in some cases, provincial guidelines or physician discretion.

What Are the Eligibility Criteria for a Tirzepatide Prescription for Type 2 Diabetes?

For its brand name Mounjaro, tirzepatide is indicated for individuals with Type 2 diabetes mellitus. The primary eligibility criterion is a diagnosis of Type 2 diabetes.

Diagnosis of Type 2 Diabetes: Patients must have a confirmed diagnosis of Type 2 diabetes. This is typically based on blood tests measuring fasting blood glucose, HbA1c levels, or oral glucose tolerance tests.
Adjunct to Diet and Exercise: Mounjaro is approved for use as an adjunct to diet and exercise. This means it's intended to be part of a broader lifestyle modification plan, not a standalone treatment.
Any BMI: Unlike the weight loss indication, there is no specific BMI threshold for patients with Type 2 diabetes to qualify for Mounjaro. While many individuals with Type 2 diabetes are overweight or obese, Mounjaro can be prescribed to diabetic patients across the BMI spectrum if deemed appropriate by their physician.
Inadequate Glycemic Control: Often, Mounjaro is considered when other first-line diabetes medications (such as metformin) are insufficient to achieve target blood glucose levels, or when patients experience side effects from other treatments. It can be used as monotherapy or in combination with other anti-diabetic agents.

It's important to note that while Mounjaro often leads to significant weight loss in diabetic patients, its primary approved indication here is glycemic control.

What Are the Eligibility Criteria for a Tirzepatide Prescription for Obesity Management?

For its brand name Zepbound, tirzepatide is specifically indicated for chronic weight management in adults who meet certain BMI and comorbidity criteria.

BMI Thresholds:
- Obesity: A Body Mass Index (BMI) of 30 kg/m² or greater.
- Overweight with Comorbidities: A BMI of 27 kg/m² or greater AND at least one weight-related comorbidity.
What are Weight-Related Comorbidities? These are health conditions that are caused or worsened by excess weight. Common examples include:
- Hypertension (High Blood Pressure): A chronic medical condition in which the blood pressure in the arteries is persistently elevated.
- Dyslipidemia: An abnormal amount of lipids (e.g., triglycerides, cholesterol) in the blood.
- Obstructive Sleep Apnea: A condition in which a person repeatedly stops breathing for short periods during sleep, often due to excess weight around the neck.
- Established Cardiovascular Disease: Conditions affecting the heart or blood vessels, such as coronary artery disease, history of heart attack, or stroke.
Adjunct to Diet and Exercise: Like Mounjaro, Zepbound is intended to be used in conjunction with a reduced-calorie diet and increased physical activity. It is not a substitute for lifestyle changes.
No Type 2 Diabetes Required: Crucially, individuals seeking Zepbound for weight management do not need to have Type 2 diabetes, provided they meet the BMI and comorbidity criteria.

Understanding BMI: BMI is a measure that uses your height and weight to work out if your weight is healthy. It's calculated as weight (kg) / [height (m)]². While a useful screening tool, it does not directly measure body fat or health, and a healthcare provider will consider other factors.

Contraindications:
Regardless of the indication, there are certain conditions where tirzepatide should not be used:

Personal or family history of medullary thyroid carcinoma (MTC).
Patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
History of severe hypersensitivity reaction to tirzepatide or any of its components.
Patients with a history of pancreatitis should be carefully evaluated, as GLP-1 agonists have been associated with pancreatitis.

Ultimately, the decision to prescribe tirzepatide rests with a qualified healthcare provider in BC. They will conduct a thorough medical evaluation, review your medical history, assess your current health status, and discuss the potential benefits and risks to determine if tirzepatide is an appropriate and safe treatment option for you.

How to Get a Tirzepatide Prescription in BC

Once you and your healthcare provider have determined that tirzepatide is a suitable treatment option, the next step is to obtain a prescription. In British Columbia, there are several pathways to achieve this, ranging from your family doctor to specialized clinics and telemedicine services.

Can My Family Doctor (GP) Prescribe Tirzepatide?

Yes, your General Practitioner (GP) or family doctor can prescribe tirzepatide in British Columbia. For many patients, especially those with Type 2 diabetes or those with straightforward obesity criteria, their GP will be the first and often primary point of contact.

Initial Assessment: Your GP will conduct a thorough medical assessment, including reviewing your medical history, current medications, lifestyle, and any relevant blood tests (e.g., HbA1c for diabetes, lipid panel, kidney function). They will also confirm your eligibility based on the criteria outlined above (Type 2 diabetes, or BMI with comorbidities).
Discussion of Risks and Benefits: Your GP will discuss the potential benefits of tirzepatide, its common side effects, and rare but serious risks. They will also explain proper injection technique and titration schedule.
Ongoing Monitoring: If prescribed, your GP will typically manage your ongoing treatment, including monitoring your progress, adjusting the dose as needed, and managing any side effects. Regular follow-up appointments will be essential.
Referral to Specialists: In more complex cases, or if your GP feels further specialized input is needed, they may refer you to an endocrinologist or a weight management specialist.

Should I See an Endocrinologist or a Weight Management Specialist?

While your GP can prescribe tirzepatide, a referral to a specialist might be beneficial or even necessary in certain situations:

Endocrinologist: An endocrinologist is a specialist in hormones and metabolic disorders, including diabetes and obesity.
- When to see one: If you have complex Type 2 diabetes (e.g., difficulty achieving glycemic control with multiple medications, significant complications), or if you have other endocrine disorders contributing to your weight or metabolic health, an endocrinologist can provide expert guidance and manage your tirzepatide prescription. They are particularly adept at fine-tuning diabetes treatment plans.
Weight Management Clinics/Specialists: These clinics often have a multidisciplinary team (doctors, dietitians, exercise physiologists, psychologists) focused on comprehensive obesity care.
- When to see one: If your primary goal is weight loss and you meet the criteria for Zepbound, a specialized weight management clinic can offer a holistic approach beyond just medication. They can provide structured diet and exercise plans, behavioural therapy, and long-term support, which are crucial for sustained weight loss. Vancouver clinics and other major cities in BC often have such private weight management clinics. These clinics are well-versed in the prescribing protocols for GLP-1/GIP agonists like tirzepatide.

Accessing specialists often requires a referral from your GP, especially for publicly funded specialist visits. Private weight management clinics might allow direct booking but will involve out-of-pocket fees for consultations.

Can I Get a Tirzepatide Prescription Through Telemedicine Services in BC?

Yes, telemedicine platforms have become a viable option for obtaining a tirzepatide prescription in BC, particularly for those seeking convenience or who have difficulty accessing in-person care. Several prominent telemedicine services operate in Canada and can facilitate prescriptions for tirzepatide, provided you meet the eligibility criteria.

Examples of telemedicine platforms that can connect